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ABSTRACT
Background: NSAIDs are a significant cause of drug-related hospital ad-
missions and deaths. The therapeutic effects of NSAIDs have been associated
with the risk for developing adverse events, mainly in the gastrointestinal
tract.
Objectives: The focus of this study was to identify the most common risk
factors associated with NSAID-induced upper gastrointestinal bleeding (UGIB)
resulting in hospital admissions. A secondary end point was the relationship
between use of gastroprotective treatment and relevant risk factors to NSAID-
induced UGIB in the selected population.
Methods: This study was a cross-sectional, retrospective, case-series analy-
sis of NSAID-induced UGIB resulting in hospital admission to the Requena
General Hospital, Valencia, Spain, occurring from 1997 to 2005. International
Classification of Diseases, Ninth Revision, Clinical Modification codes were used
to identify UGIB admissions associated with NSAIDs. To estimate the probabil-
ity of association between UGIB and the use of NSAIDs, the Naranjo adverse
drug reaction probability was used. Patients were categorized as high-risk to
develop UGIB if they met ≥1 of the following risk criteria (relevant risk factors):
aged ≥65 years (age risk factor); peptic ulcer disease or NSAID gastropathy
occurring in the year before their hospital admission (history risk factor); and
concomitant use of other NSAIDs, systemic corticoids, oral anticoagulants, or
platelet aggregation inhibitors (concomitant medication risk factor). Patients
were categorized as candidates to use gastroprotections if they met ≥1 of the
relevant risk factors. Patients were categorized as users of gastroprotective
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treatment if they used proton pump inhibitors, histamine H2-receptor antago-
nists, or misoprostol at hospital admission.
Results: This study comprised 209 cases of NSAID-induced UGIB (129 men,
80 women; mean [SD] age, 71.5 [13.8] years; 128 [61.2%] receiving acetyl sali-
cylic acid [ASA], with 72 [34.4%] receiving low-dose [80–325 mg] ASA). Preva-
lence of relevant risk factors for UGIB were as follows: age, 158 (75.6%) patients;
history, 37 (17.7%); and concomitant medication, 35 (16.7%). One hundred
seventy-eight (85.2%) patients met ≥1 criterion for using a gastroprotective agent;
28 (15.6%) were actually using one. Only the history risk factor was significantly
associated with the use of gastroprotective treatment (P = 0.007; odds ratio =
3.17).
Conclusions: In this study of NSAID-induced UGIB resulting in hospital admis-
sion, age was the most common risk factor. However, this criterion was not
associated with the use of gastroprotective agents. A large number of cases
were associated with the use of ASA, primarily in those receiving low doses. A
significant lack of gastroprotective agent use was observed in patients who met
the criteria to use them. (Curr Ther Res Clin Exp. 2007;68:107–119) Copyright ©
2007 Excerpta Medica, Inc.
Key words: nonsteroidal anti-inflammatory drugs, upper gastrointestinal
bleeding, hospital admissions, elderly, risk factors.
INTRODUCTION
NSAIDs have been found to be a significant cause of drug-related hospital ad-
missions and deaths.1,2 In Spain, NSAIDs are the most consumed drugs and are
sixth in pharmaceutical expenditure.3 They are considered the therapeutic class
of drugs that is most frequently associated with self-medication, many times
without an adequate analysis of risk-benefit. This especially has been found
with the use of acetylsalicylic acid (ASA), which is a component of many over-
the-counter (OTC) medicines.4,5
The therapeutic effects of NSAIDs have been associated with the risk for
developing adverse events (AEs), mainly in the gastrointestinal (GI) tract,6 such
as NSAID gastropathy. This ranges from dyspeptic symptoms or signs to serious
complications (eg, peptic ulcer or upper GI bleeding [UGIB]).7 In a meta-analysis8
of 24 randomized controlled trials, it was suggested that about 1 out of 100 pa-
tients who used ASA for a mean of 28 months developed UGIB. Peptic ulcers
and UGIB might require hospitalization and have been associated with morbid-
ity and mortality.9 Approximately 15% to 30% of users of traditional NSAIDs
develop mucosal injury associated with UGIB.2 The relative increase in risk for
GIB among NSAIDs users is estimated to be 4-fold.2 An increased prevalence of
NSAID toxicity also has been observed in elderly patients.10 The prevalence of
UGIB in elderly patients varies from 2.5% to 4.5%.11
The most relevant risk factors of developing NSAID-induced UGIB
are2,4,6,7,11,12: (1) age ≥65 years12–14 (age >60 years for some scientific associa-
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tions4,15); (2) prior occurrence or history of peptic ulcer disease, including
previous GI hemorrhage associated with NSAIDs12,13,16; and (3) concomitant
use of other medications—systemic corticoids,13 oral anticoagulants,17 clopi-
dogrel or ticlopidine,18 alendronate,19 or other NSAIDs, including low-dose
ASA (80–325 mg/d)20 (for ASA, the effect is dose-dependent8,21).
A search of MEDLINE and PUBMED was conducted for literature in the
English or Spanish language published between January 1996 and December
2006 using the key terms nonsteroidal anti-inflammatory drug, gastrointestinal
bleeding, and prevention [or prophylaxis]. From this search we identified recom-
mendations or indications for the use of gastroprotective medications. The
Spanish Association of Gastroenterology and the Spanish Society of Rheumatology
recommend gastroprotective treatment use in patients aged >60 years who use, or
will use, cyclooxygenase-2 (COX-2) nonselective-inhibitor NSAIDs, independent
of the presence or absence of other risk factors.15 Similarly, current UK clinical
guidance12 on NSAID use recommends gastroprotective treatment use in patients
at high risk for NSAID-induced GI AEs (aged ≥65 years, history of gastroduode-
nal ulcer, GI bleeding, or gastroduodenal perforation, and/or use of concomitant
medications that are known to increase the likelihood of upper-GI AEs).
However, this evidence of the efficacy of gastroprotective treatment reducing
UGIB is associated only with the use of coxibs.22,23 Although the evidence of ef-
ficacy is limited, the lack of large-outcome studies to the contrary suggests
that it does not take effect. Some systematic reviews24,25 suggest that using a pro-
ton pump inhibitor and administering a double dose of histamine H2-receptor
antagonists or misoprostol are effective for preventing chronic NSAID-related
endoscopic gastric and duodenal ulcers.
Additional risk factors for NSAID-induced UGIB include renal or liver dysfunc-
tion, cigarette smoking, high doses of NSAIDs, and chronic use of NSAIDs.2,6–8,12,19
As a consequence of the severity and frequency of UGIB, it is necessary to
establish mechanisms to identify patients who are at high risk for developing
NSAID-induced UGIB, and then employ preventive interventions which have been
demonstrated as useful, such as gastroprotective treatment.12,15,25,26 Since 1997,
the Requena Hospital Pharmacy Service (Valencia, Spain) has maintained a data-
base of drug-related UGIB resulting in hospital admissions. The aims of this study
were to identify the most common risk factors associated with NSAID-induced
UGIB resulting in hospital admissions and to explore the relationship between the
use of gastroprotective treatment and relevant risk factors to NSAID-induced UGIB.
METHODS
Study Design
This study was a cross-sectional, retrospective, case-series analysis of
NSAID-induced UGIB resulting in hospital admission to the Requena General
Hospital, Valencia, Spain, occurring from 1997 to 2005. The health area of the
hospital includes ~53,000 inhabitants. It is a rural zone, very dispersed, and dis-
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tant from other hospitals. Cases of UGIB resulting in hospital admissions were
determined following the same method as our previously published study1 on
drug-related UGIB resulting in hospital admissions. This study protocol was
reviewed and approved by the Requena General Hospital Research Commission.
Detection System, Analysis and Verification of Cases of UGIB
A trained group of 1 physician (B.B.) and 2 pharmacists (J.L.M. and A.C.) fol-
lowed a standardized approach to data collection. To detect UGIB hospital
admissions associated with the use of NSAIDs, 1 physician (B.B.) reviewed the
hospital admissions registration book on a monthly basis, searching for diag-
noses of UGIB and those associated with UGIB, such as hematemesis (vomiting
of blood) or melena (blood in stool).
To garner more GI bleeding admissions associated with NSAIDs and to dis-
card nonbleeding and chronic diagnosis, 2 pharmacists (J.L.M. and A.C.) also
reviewed the database of the clinical documentation department of the hospi-
tal on a monthly basis, searching for and identifying completed consultations
with primary and secondary diagnosis codes according to International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).27
The main or primary ICD-9-CM diagnosis codes identified were as follows:
530.21, ulcer of esophagus (fungal, peptic) with bleeding; ulcer of esophagus due
to ingestion of aspirin, chemicals, or medicines; 530.82, esophageal hemorrhage;
578.0, hematemesis; 578.1, melena; 578.9, hemorrhage of gastrointestinal tract,
unspecified (gastric hemorrhage, intestinal hemorrhage); 531.0, acute gastric
ulcer with hemorrhage; 531.00, acute gastric ulcer with hemorrhage, without men-
tion of obstruction; 531.01, acute gastric ulcer with hemorrhage, with obstruction;
531.2, acute gastric ulcer with hemorrhage, with obstruction; 531.20, acute gas-
tric ulcer with hemorrhage and perforation, without mention of obstruction;
531.21, acute gastric ulcer with hemorrhage and perforation, with obstruction;
533.0, acute peptic ulcer of unspecified site with hemorrhage (533.00 and 533.01,
without or with mention of obstruction, respectively); 533.1, acute peptic ulcer
of unspecified site with perforation (533.10 and 533.11, without or with mention
of obstruction, respectively); 533.2, acute peptic ulcer of unspecified site with
hemorrhage and perforation (533.20 and 533.21, without or with mention of
obstruction, respectively); 534.0, gastrojejunal ulcer with hemorrhage (534.00
and 534.01, without or with mention of obstruction, respectively); 534.1, acute
gastrojejunal ulcer with perforation (534.10 and 534.11, without or with mention
of obstruction, respectively); 534.2, acute gastrojejunal ulcer with hemorrhage
and perforation (534.20 and 534.21, without or with mention of obstruction,
respectively); and 535.01, acute gastritis with hemorrhage.
Secondary diagnosis codes were as follows: E935.3, analgesics, antipyretics,
and antirheumatics causing adverse effects in therapeutic use; E935.4, aromatic
analgesics causing adverse effects in therapeutic use (acetanilid, paracetamol
[acetaminophen], and phenacetin [acetophenetidin]); E935.5, pyrazole deriva-
tives causing adverse effects in therapeutic use (aminophenazone [aminopyrine],
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phenylbutazone); E935.6, antirheumatics (antiphlogistics) causing adverse
effects in therapeutic use (gold salts, indomethacin); E935.7, other non-narcotic
analgesics causing adverse effects in therapeutic use (aminopyrine-barbital
complex); E935.8, other specified analgesics and antipyretics causing adverse
effects in therapeutic use (pentazocine); and E935.9, unspecified analgesic and
antipyretic causing adverse effects in therapeutic use.
One physician (B.B.) and 1 pharmacist (A.C.) checked all patient medical
records to gather the necessary data regarding treatment and diagnoses. To
estimate the probability of association between UGIB and the use of NSAIDs, the
Naranjo adverse drug reaction probability28 was used: a score of 1 to 4, possi-
ble; a score of 5 to 8, probable; and a score of ≥9, definite. A score of ≥5 was con-
sidered criteria for positive association between UGIB and NSAID use.
Study Population
All cases of drug-related UGIB resulting in hospital admission deemed to be
associated with the use of NSAIDs were selected. Patients with UGIB associated
with other drugs or without relevant information for the analysis were excluded.
Instruments
Information from UGIB cases associated with NSAIDs was collected using a
data collection sheet. The patient data collected were as follows: age, sex, num-
ber of hospitalization days, current or historical diseases, concomitant use of
other medication (NSAIDs, systemic corticoids, oral anticoagulants, platelet
aggregation inhibitors), use of gastroprotective treatment (proton pump
inhibitor, histamine H2-receptor antagonists, or misoprostol),
23–25 and alcohol
and tobacco consumption.
Patients were categorized as high-risk to develop an UGIB if they met ≥1 of the
following risk criteria (relevant risk factors): aged ≥65 years (age risk factor)12–14;
peptic ulcer disease or NSAID gastropathy occurring in the year before their hos-
pital admission (history risk factor)12,13,16; and concomitant use of other NSAIDs,
systemic corticoids, oral anticoagulants, or platelet aggregation inhibitors (con-
comitant medication risk factor).12,13,17–20 Patients were categorized as candidates
to use gastroprotections if they met ≥1 of the relevant risk factors. Patients were
categorized as users of gastroprotective treatment if they used proton pump
inhibitors, histamine H2-receptor antagonists, or misoprostol at hospital admis-
sion.23–25 Patients with a history of heart failure, cerebrovascular disease, coro-
nary disease, chronic obstructive lung disease, cirrhosis, or renal failure were
categorized as patients with associated comorbidities.12
The information collected regarding NSAIDs used was as follows: brand and
generic name, dosage schedules, number of days of treatment, and drug dis-
pensing category (OTC or prescription drugs). The NSAIDs were also grouped
as traditional NSAIDs (all NSAIDs, excluding ASA), ASA used as a platelet antiag-
gregate (doses between 80–325 mg/d), and ASA used as an analgesic or anti-
inflammatory (doses >375 mg/d).
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Statistical Analyses
Using patient and NSAID data, a database was created with Microsoft Office
Access® 2003 (Microsoft Corporation, Seattle, Washington). Statistical analyses
were performed using SPSS for Windows version 13.0 (SPSS Inc., Chicago,
Illinois). Data were reported as mean (SD) or as percentage. The χ2 test was
used to compare proportions, and the Student t test was used to compare
means, including odds ratio (OR) and 95% CI. Comparisons were analyzed using
a 2-tail test and P < 0.05 was considered statistically significant. The Fisher
exact test was used to compare categories that had <5 data sets. With a 95% CI,
an OR of 3.0, and the number of patients included, this cross-sectional analysis
had a power of 95% to detect significant differences between the use of gastro-
protective agents in those patients with relevant risk factors and those without
relevant risk factors.2,12,13,25
RESULTS
Two hundred twenty-six cases of drug-associated UGIB were found in the hospi-
tal database. Of these, 209 (92.5%) were attributed to NSAIDs, 4 (1.9%) were attrib-
uted to acetaminophen, 4 (1.9%) to metamizol, 3 (1.4%) to ticlopidine, and 3 (1.4%)
to clopidogrel. In 3 (1.4%) cases the NSAID was not identified, as the only infor-
mation appearing in the patients’ clinical records was NSAID with no specific
brand or generic name given. Of the 209 cases attributed to NSAIDs, 81 (38.8%)
were associated with traditional NSAIDs, 72 (34.4%) to ASA with doses between
80 and 325 mg/d, and 56 (26.8%) to ASA with doses >325 mg/d. No selective 
COX-2–inhibiting drugs were associated with UGIB in this population.
This cross-sectional analysis comprised 209 cases (129 men, 80 women;
mean [SD] age, 71.5 [13.8] years, median [range], 73 [25–98] years; mean [SD]
hospitalization days, 4.6 [2.8], median [range], 4 [1–22] hospitalization days) of
UGIB associated with NSAIDs, which occurred from 1997 to 2005. Table I shows
the demographic and clinical characteristics with regard to sex.
Patients’ Relevant Risk Factors for UGIB
Patients had a mean (SD) number of relevant risk factors of 1.1 (0.6); range,
0 to 3; median, 1.0; and mode, 1.0. The frequency of those risk factors were: age,
110 (52.6%); history, 11 (5.3%); concomitant medication, 8 (3.8%); age and his-
tory, 22 (10.5%); age and concomitant medication, 23 (11.0%); history and con-
comitant medication, 1 (0.5%); and age, history, and concomitant medication, 3
(1.4%). According to sex, there were no differences in the distribution or mean
number of relevant risk factors, associated comorbidities, or cases associated
with the use of OTC NSAIDs (Table I).
Indication and Use of Gastroprotective Medications
One hundred seventy-eight (85.2%) patients met ≥1 criterion for using a gas-
troprotective agent; 28 (15.7%) patients were actually using one. Among those
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28 patients, all had an indication to use it. The gastroprotective agents used
were: proton pump inhibitors, 18 (64.3%); histamine H2-receptor antagonists, 
9 (32.1%); and misoprostol, 1 (3.6%). In the 31 patients without an indication to
use gastroprotection, there were no patients using one. With regard to sex, there
were no differences between the indication and use of gastroprotective treat-
ment (Tables I and II).
Risk Factors and Use of Gastroprotective Agents
Age Risk Factor
Among the 158 (75.6%) patients aged ≥65 years, 23 (14.6%) were using gas-
troprotective medications. Also, 5 (9.8%) of the 51 patients aged <65 years were
using gastroprotective medications. Therefore, there were no significant differ-
Table I. Demographic and clinical characteristics of patients admitted to the hospital
for NSAID-induced upper gastrointestinal bleeding (UGIB).
Male Female All Patients
Variable (n = 129) (n = 80) (N = 209)
Age, mean (SD), y 72.3 (12.8) 70.2 (15.3) 71.5 (13.8)
Age, no. (%), y
≥75 59 (45.7) 36 (45.0) 95 (45.5)
65–74 41 (31.8) 22 (27.5) 63 (30.1)
60–64 10 (7.8) 8 (10.0) 18 (8.6)
45–59 13 (10.1) 8 (10.0) 21 (10.0)
25–44 6 (4.7) 6 (7.5) 12 (5.7)
UGIB relevant risk factors,*†‡
mean (SD) 1.1 (0.6) 1.1 (0.7) 1.1 (0.6)
Distribution of the UGIB-relevant 
risk factors, no. (%)
Age* 100 (77.5) 58 (72.5) 158 (75.6)
History† 24 (18.6) 13 (16.3) 37 (17.7)
Concomitant medication‡ 19 (14.7) 16 (20.0) 35 (16.7)
None 18 (14.0) 13 (16.3) 31 (14.8)
Associated comorbidities,§ no. (%) 24 (18.6) 7 (8.8) 31 (14.8)
OTC drug use, no. (%) 32 (24.8) 18 (22.5) 50 (23.9)
Indication to the use of 
gastroprotective agents, no. (%) 111 (86.0) 67 (83.8) 178 (85.2)
Actual use of gastroprotective agents,
no. (%) 15 (11.6) 13 (16.3) 28 (13.4)
OTC = over-the-counter.
*Aged ≥65 years.
†Presence or history of acid peptic disease, including previous gastrointestinal hemorrhage associated
with NSAIDs.
‡Concomitant use of systemic corticoids, oral anticoagulants, clopidogrel, or other NSAIDs.
§Heart failure, cerebrovascular disease, coronary disease, chronic obstructive lung disease, cirrhosis, or
renal failure.
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ences between those with the age risk factor and those without (Table II). In
patients aged ≥75 years, the percentage of gastroprotective agent use
(14.7%) was similar to the percentage of patients aged ≥65 years who were
using them (14.5%). The mean (SD) age was similar in the 28 patients who
used gastroprotection compared with those 181 patients who did not (72.0
[13.4] vs 71.4 [13.9]).
History Risk Factor
Among the 37 (17.7%) patients with the history risk factor, 27.0% (10/37)
were using a gastroprotective agent. This percentage was significantly larger
than that of the 10.5% (18/172) of patients without the history risk factor who
were using a gastroprotective agent (P = 0.007; OR = 3.17; 95% CI, 1.21–8.24)
(Table II).
Concomitant Medication Risk Factor
Among the 35 (16.7%) patients with a concomitant medication risk factor,
20.0% (7/35) were using a gastroprotective agent. This percentage was larger than
that of patients without this risk factor who were using a gastroprotective agent
(12.1% [21/174]) (Table II), but the difference was not statistically significant.
Associated Comorbidities 
Of the 31 (14.8%) patients with associated comorbidities, 12.9% (4/31) were
using a gastroprotective agent. This was similar to the percentage of patients with-
out this risk factor who were using a gastroprotective agent (13.5% [24/178])
(Table II).
OTC NSAIDs
Of the 50 (23.9%) cases of UGIB that were associated with OTC NSAIDs, 40
(80.0%) patients had an indication to use gastroprotective agents. Of those
patients, 5.0% (2/40) were using gastroprotective medications. Of the 159 cases
of UGIB associated with prescription NSAIDs, 139 (87.4%) patients had an indi-
cation to use gastroprotective agents, of those, 26 (18.7%) were using gastro-
protective medications. Consequently, there were no significant differences
between the use of OTC and prescription NSAIDs with regard to the indication
to use gastroprotective agents (80.0% vs 87.4%). However, in the patients with
an indication to use gastroprotective agents, a significantly larger percentage of
the prescription NSAID patients were actually using a gastroprotective agent
(18.7%) when compared with the percentage of OTC NSAID patients (5.0%) (P =
0.036; OR = 0.23; 95% CI, 0.02–0.99). 
Similarly, of the 50 patients with UGIB associated with OTC NSAIDs, only 4.0%
(2/50) were using a gastroprotective agent. This percentage was significantly
lower than the 16.4% (26/159) of patients with UGIB associated with prescrip-
tion NSAIDs who were using gastroprotective medications (P = 0.025; OR = 0.21;
95% CI, 0.02–0.91) (Table II).
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DISCUSSION
This study selected patients who were hospitalized for UGIB and retrospec-
tively describes patient characteristics and risk factor profiles of 209 cases of
NSAID-induced UGIB that resulted in hospital admissions to Requena General
Hospital, Valencia, Spain. This study explored associations between the use of
gastroprotective treatment and relevant risk factors to NSAID-induced UGIB;
therefore, the results do not imply causations. Among the cases examined,
most (128 [61.2%]) were associated with the use of ASA, mainly (72 [56.3%])
with low doses (80–325 mg/d). This result suggests the need to dispense this
drug, including OTC products, with the same caution as any other NSAID.5,29
Additionally, 50 cases of NSAID-induced UGIB were associated with OTC NSAIDs
(40 cases with an indication of gastric protection and 2 cases actually using
gastroprotection treatment). These findings suggest the need to implement pro-
grams of pharmaceutical care focused on the use of oral nonprescription anal-
gesics at a community pharmacy level.4
Although a majority (61.7% [129/209]) of the UGIB cases was in male patients,
the frequency of the relevant risk factors of NSAID-induced UGIB did not vary
according to patient sex.
In this group of NSAID-induced UGIB cases, we found a significant lack of use
of gastroprotective agents in patients who met the criteria to use them (84.8%
[151/178]). However, this study selected patients who were hospitalized for UGIB
and this finding might be expected. In our study, patients’ mean (SD) age, 71.5
(13.8) years, was similar to that reported by Lim and Heatley30 (70.5 [15.2] years)
in a group of 43 patients who used NSAIDs and developed GI hemorrhage identi-
fied by endoscopy. Although age was the most frequent risk factor in our study,
this criterion was not associated with the use of gastroprotective agents. In a
study by Laine et al,13 the relative risk for developing NSAID-induced GI hemor-
rhage in persons between 65 and 74 years old was found to be 2.4, and 3.9 in per-
sons aged >74 years. In fact, among the 3 risk factors and criteria that indicated its
use, only the history risk factor was significantly associated with the use of gastro-
protective medications. This differs from recommendations12,15 and published
works13,17,20,25 that suggest that the use of gastroprotective cotherapy should be
considered in patients at high risk for developing NSAID-induced UGIB. It also sug-
gests the need to carry out informative and educational activities to improve the
use of this preventive intervention in this group of patients.
In this study, 14.5% of patients aged ≥65 years used gastroprotection, a per-
centage that was mirrored in patients aged ≥75 years (14.7%). This frequency is
apparently lower than the 36% of patients aged ≥75 years reported by Hartnell
et al.31 The difference might be associated with the type of population studied;
the study by Hartnell et al examined patients aged ≥65 years receiving treat-
ment with antiarthritic drugs. In turn, in our study, the total percentage of
patients who were using gastroprotective medication (13.4%) was similar to the
11% reported by Lim and Heatley.30 These results suggest the under-use of this
preventive intervention. Due to the lack of strong evidence,22,23 it is necessary to
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develop clinical trials that will assess the effectiveness of this strategy. Studies
comparing the assessment of practice (eg, use of gastroprotective agent with
selective COX-2–inhibiting drugs), patient preference, long-term tolerance, and
the cost-effectiveness of gastroprotective therapies are also needed.32
In 84.2% (176/209) of the cases of NSAID-induced UGIB, the age of the patients
was >60 years. This is in agreement with recommendations15 made by the
Spanish Association of Gastroenterology and the Spanish Rheumatology Society
for using preventive interventions in patients aged >60 years. These recommenda-
tions should be assessed in a prospective, longitudinal, controlled study to com-
pare the tolerability of NSAIDs plus gastroprotective treatment versus NSAIDs
alone in this age group.
Study Limitations
Because our study had several limitations, the results must be interpreted
with caution. This study included only patients who were hospitalized for UGIB,
so there is an important selection bias inherent in this population. This study was
a cross-sectional analysis of retrospective case series, therefore, it lacked a control
group; causal associations could not be established. In the majority of the cases
observed (89.5% [187/209]), the estimating probability of NSAID-induced UGIB was
probable (5–8 points using the Naranjo adverse drug reaction probability scale).
Some statistical analyses and comparisons were conducted in a very small num-
ber of cases, so the analysis was likely underpowered to detect differences. Finally,
the absence of fixed information on clinical factors, such as precise NSAID sched-
ules, adherence to NSAID treatment, Helicobacter pylori assessment, and smoking
and alcohol consumption, might have resulted in an underestimation of the risk
for UGIB. Therefore, it is probable that some patients were on gastroprotective
medications just before admission but were not recorded as such on the data col-
lection sheet.
CONCLUSIONS
In this retrospective analysis of database case series of NSAID-induced UGIB result-
ing in hospital admission, age was the most common risk factor. However, this cri-
terion was not associated with the use of gastroprotective agents. A significant lack
of gastroprotective agent use was observed in patients who met the criteria to use
them (84.8% [151/178]). A large number of cases (61.2% [128/209]) were associated
with the use of ASA, primarily in those receiving low doses (80–325 mg/d).
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